News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
259,026 Results
Type
Article (13491)
Company Profile (103)
Press Release (245432)
Section
Business (87836)
Career Advice (460)
Deals (15317)
Drug Delivery (60)
Drug Development (36475)
Employer Resources (49)
FDA (6235)
Job Trends (6178)
News (149762)
Policy (13993)
Tag
Academia (435)
Africa (312)
Alliances (23043)
Alzheimer's disease (325)
Approvals (6215)
Arizona (35)
Artificial intelligence (40)
Asia (19645)
Australia (2533)
Bankruptcy (143)
Best Places to Work (4207)
Biosimilars (31)
Biotechnology (44)
C2C Services and Suppliers (10597)
California (611)
Canada (440)
Cancer (155)
Career advice (402)
Cell therapy (23)
China (69)
Clinical research (30064)
Collaboration (55)
Compensation (27)
Connecticut (25)
COVID-19 (738)
Cystic fibrosis (22)
Data (109)
Diabetes (27)
Diagnostics (1202)
Drug pricing (48)
Earnings (31141)
Employer resources (43)
Europe (38411)
Events (36277)
Executive appointments (86)
FDA (6307)
Florida (76)
Funding (39)
Gene therapy (41)
GLP-1 (262)
Government (1250)
Healthcare (3508)
Hotbed/Location (177911)
Illinois (70)
Indiana (59)
Infectious disease (742)
Inflammatory bowel disease (41)
Interviews (57)
IPO (5782)
Job creations (2046)
Job search strategy (371)
Kansas (49)
Layoffs (164)
Legal (3398)
Lung cancer (33)
Manufacturing (46)
Maryland (92)
Massachusetts (536)
Medical device (1251)
Medtech (1253)
Mergers & acquisitions (9479)
Metabolic disorders (103)
Minnesota (37)
Neuroscience (379)
New Jersey (255)
New York (170)
NextGen Class of 2024 (1577)
Non-profit (588)
North Carolina (226)
Northern California (269)
Obesity (63)
Ohio (29)
Opinion (106)
Patents (40)
Pennsylvania (188)
People (28244)
Pharmaceutical (59)
Phase I (7822)
Phase II (12709)
Phase III (11419)
Pipeline (52)
Podcasts (36)
Policy (37)
Postmarket research (1398)
Preclinical (3132)
Press Release (25)
Rare diseases (52)
Real estate (2625)
Regulatory (9693)
Research institute (561)
Resumes & cover letters (55)
South America (497)
Southern California (272)
Startups (1624)
Texas (82)
United States (2700)
Vaccines (92)
Virginia (22)
Washington State (48)
Weight loss (55)
Date
Today (45)
Last 7 days (216)
Last 30 days (819)
Last 365 days (13310)
2024 (9379)
2023 (14245)
2022 (19556)
2021 (20068)
2020 (19033)
2019 (14887)
2018 (11713)
2017 (13890)
2016 (13132)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
259,026 Results for "aurinia pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Aurinia Pharmaceuticals Shareholder Urges Fellow Shareholders to Withhold Support for CEO Peter Greenleaf
Lucien Selce, who owns approximately 2.2% of the outstanding shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”), today issued the following letter to Aurinia shareholders.
June 3, 2024
·
4 min read
BioCapital
Aurinia Announces 2024 Annual General Meeting Results
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024.
June 14, 2024
·
2 min read
Business
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
Aurinia Pharmaceuticals Inc. issued its financial results for the first quarter ended March 31, 2024.
May 2, 2024
·
22 min read
BioCapital
Aurinia Provides Update on Proxy Statement
Aurinia Pharmaceuticals Inc. filed a supplement to the Company’s Management Information and Proxy Statement dated June 3, 2024 for its Annual General Meeting of Shareholders to be held on June 14, 2024.
June 3, 2024
·
1 min read
BioCapital
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
Aurinia Pharmaceuticals Inc. announced that it will attend the 2024 Jefferies Global Healthcare Conference in New York from June 4-6, 2024.
May 30, 2024
·
1 min read
Business
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
Aurinia Pharmaceuticals Inc. announced that it will release financial and operational results for the first quarter of 2024 on Thursday, May 2, 2024, before markets open.
April 15, 2024
·
1 min read
Press Releases
Aurinia Announces Board Restructuring
September 13, 2024
·
2 min read
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
Aurinia Pharmaceuticals Inc. announced that it will attend the 2024 RBC Capital Markets Global Healthcare Conference in New York from May 14-15, 2024.
May 7, 2024
·
1 min read
BioCapital
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
Aurinia Pharmaceuticals Inc., announced an oral presentation at the European Alliance of Associations for Rheumatology 2024 taking place in Vienna, Austria June 12-15.
June 5, 2024
·
7 min read
BioCapital
Aurinia to Participate in Upcoming Investor Healthcare Conferences
Aurinia Pharmaceuticals Inc. today announced that management will be participating in the following upcoming investor conferences during the month of March.
February 27, 2024
·
1 min read
1 of 25,903
Next
